| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2012: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2011: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Research Abstract |
In order to identify novel therapeutic target(s) for AIDS/HIV-infection, we have analyzed detailed molecular mechanisms of anti-viral activity of HIV restriction factor TRIM5alpha. We were able to obtain following results: 1.In situ uncoating assay revealed that an HIV-1 mutant strain, which could replicate in the presence of monkey TRIM5alpha, showed delayed uncoating process. 2. A naturally occurring single amino acid substitution in human TRIM5alpha linker region between coiled-coil and SPRY regions affects its anti-HIV-1 activity. 3. TRIM5alpha could bind to TAB2, which is in the TLR4-mediated signal transduction pathway, probably through its SPRY region.
|
